Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

40.95 +0.29 (+0.71%)
Official Closing Price Updated: 7:00 PM EDT, Jun 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,847,649
Open 41.03
Bid (Size) 40.95 (7)
Ask (Size) 41.38 (1)
Prev. Close 40.66
Today's Range 40.78 - 41.08
52wk Range 33.67 - 45.92
Shares Outstanding 5,385,189,617
Dividend Yield 3.53%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
Discover Cantor Fitzgerald's analysis on Innoviva, highlighting its unique royalty-based business model with GSK for asthma and COPD products. 
Via Benzinga
7 A-Rated Biotech Stocks Worth Betting on in June
A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation. 
Via InvestorPlace

Performance

YTD
+9.17%
+9.17%
1 Month
-8.16%
-8.16%
3 Month
-3.24%
-3.24%
6 Month
+12.19%
+12.19%
1 Year
+18.28%
+18.28%

More News

Read More
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
Via InvestorPlace
Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK
Via Investor's Business Daily
Exposures COVID-19
US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk
From GSK plc
Via Business Wire
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
Via InvestorPlace
Topics Economy
Exposures Economy
Large Cap BIopharmaceuticals Overview
Via Talk Markets
Topics Stocks
Exposures US Equities
GSK Stock Falls as 70,000 Zantac Lawsuits Move Forward. What to Know.
Via InvestorPlace
Topics Lawsuit
Exposures Financial Legal
GSK's Blenrep Combo Therapy Cuts Risk Of Disease Progression Or Death By Around 50% In Pretreated Multiple Myeloma
Via Benzinga
Zantac Heart Burn Continues For GSK As US Court Ruling Allows Thousands Of Zantac Lawsuits To Move Forward
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
GSK, Boston Beer And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
From GSK plc
Via Business Wire
Is Moderna Stock a Buy Now That It's a 2-Product Company?
Via The Motley Fool
Why GameStop Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
From GSK plc
Via Business Wire
Moderna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK
Via Investor's Business Daily
Exposures Product Safety
AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report
Via Benzinga
Zantac Verdict: Jury Finds No Link To Colon Cancer In Initial Trial, GSK And Boehringer Prevail In First Zantac Cancer Lawsuit
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
First Advanced Oral Treatment For Asthma - Sanofi's Investigational Drug Shows Potential
Via Benzinga
GSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims
Via Benzinga
Topics Lawsuit Whistleblower
Exposures Financial Legal
GSK's Experimental Asthma Drug Reduces Severe Attacks, Phase 3 Trial Data Shows
Via Benzinga
GSK Completely Exits Sensodyne Toothpaste Maker Haleon In $1.6B Sale
Via Benzinga
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
Via Benzinga
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.